NASDAQ: AURA - Aura Biosciences, Inc.

Rentabilität für sechs Monate: +37.13%
Sektor: Healthcare

Aktionsplan Aura Biosciences, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

Weitere Details
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

EBITDA -0.0236
Число акций ао 0.03962 млрд
P/BV 3.26
EV/EBITDA 1.37
Цена ао 7.63
ISIN US05153U1079
Сайт https://www.aurabiosciences.com
Валюта usd
IPO date 2021-10-29
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Preisänderung pro Tag: 0% (9.86)
Preisänderung pro Woche: +18.51% (8.32)
Preisänderung pro Monat: -2.09% (10.07)
Preisänderung über 3 Monate: +11.79% (8.82)
Preisänderung über sechs Monate: +37.13% (7.19)
Preisänderung pro Jahr: +15.73% (8.52)
Preisänderung seit Jahresbeginn: +23.56% (7.98)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 1.58 8
P/E 0 0
EV/EBITDA -4 0
Gesamt: 3.25

Effizienz

Name Bedeutung Grad
ROA, % -29.96 0
ROE, % -33.83 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.2337 10
Gesamt: 8.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 254.64 10
Rentabilität EPS, % 10.83 2
Gesamt: 6.4
Weitere Details

Institutionen Volumen Aktie, %
Matrix Capital Management 6922870 13.98
Eventide Asset Management LLC 5802682 11.72
Adage Capital Partners GP L.L.C. 4225000 8.53
Citadel Advisors Llc 3631294 7.34
Medicxi Ventures Management (Jersey) Ltd 3039892 6.14
Nantahala Capital Management, LLC 2643720 5.34
Blackrock Inc. 2098745 4.24
Vanguard Group Inc 1730431 3.5
Decheng Capital Management III (Cayman), LLC 1163123 2.35
Goldman Sachs Group Inc 1037299 2.1

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
Avantis International Equity ETF 0.0028 11.581970066133 3.80856
Avantis U.S Small Cap Equity ETF 0.02437 27.774101036841 1.68271
Range Cancer Therapeutics ETF 1.74943 47.24446537918 0.11955
Dimensional U.S. Core Equity 2 ETF 0.00024 30.755198832543 1.47098
Dimensional International Core Equity Market ETF 0.00084 13.085145595282 3.48343
Dimensional US Core Equity Market ETF 0.00066 30.983243755928 1.40618
Dimensional World ex U.S. Core Equity 2 ETF 0.00213 13.062098501071 3.62488
Dimensional International Core Equity 2 ETF 0.002 12.593206296603 3.69996
Dimensional International Small Cap ETF 0.02439 13.318681318681 3.34747
Dimensional U.S. Equity ETF 0.0004 31.530984204131 1.3557
AltShares Event-Driven ETF 0.97581 9.6057858816339 1.21959
DBX ETF Trust - Xtrackers International Real Estate ETF 0.06228 5.615763546798 4.01983
ProShares Hedge Replication ETF 0.0027 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.11218 34.327031588619 1.54048
iShares Russell 3000 ETF 0.00056 31.230028873917 1.43482
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund 0.01698 10.313706049416 3.85434
ProShares UltraPro Russell2000 0.00959 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 ETF 0.01 32.773459189339 1.48801



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (50 Jahre)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (53 Jahr)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (63 Jahr)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (42 Jahr)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (59 Jahre)

Adresse: United States, Boston. MA, 80 Guest Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.aurabiosciences.com